Hampshire Hospitals NHS Foundation Trust
Basingstoke, RG24 9NA, United Kingdom
NCT Number: NCT05630092
Patients with lung disease who report breathlessness on exertion are often referred for a 6MWT. Due to the nature of the 6MWT (hereon referred to as a Max-6MWT), patients are required to walk as far as they can in 6 minutes. This may lead to an inaccurate assessment of their requirement for ambulatory oxygen as this form of exercise may not correspond to their normal daily activities.
In this study, patients who are routinely referred for a Max-6MWT to investigate possible exercise-induced hypoxaemia will be invited to perform an additional walking test which is performed at their normal walking speed, referred here on in as a Nor_6MWT. We hypothesise that performing a Nor_6MWT will provide a more accurate assessment of a patients' oxygen requirement, primarily from their oxygen desaturation during the test.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Not applicable
Basingstoke, RG24 9NA, United Kingdom
Patients with lung disease who report breathlessness on exertion are often referred for a 6MWT. During this test patients are asked to walk up and down a corridor (or other flat area) for six minutes whilst their blood oxygen levels and heart rate are non-invasively measured using a pulse oximeter (finger probe) and the distance walked is measured. In addition, a questionnaire that obtains a Borg Score measures the patients perceived breathlessness and leg muscle fatigue both before and immediately following the test.
Due to the nature of the 6MWT (hereon referred to as a Max-6MWT), patients are required to walk as far as they can in 6 minutes. This may lead to an inaccurate assessment of their requirement for ambulatory oxygen as this form of exercise may not correspond to their normal daily activities. It may also not accurately measure the normal changes in oxygen saturation (or desaturation) that occurs in these patients during their normal daily activities (such as walking to the shops, walking up the stairs, gardening).
In this study, patients who are routinely referred for a Max-6MWT to investigate possible exercise-induced hypoxaemia will be invited to perform an additional walking test which is performed at their normal walking speed, referred here on in as a Nor_6MWT. We hypothesise that performing a Nor_6MWT will provide a more accurate assessment of a patients' oxygen requirement, primarily from their oxygen desaturation during the test.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.
Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
Time frame: During the walk test
Continuous monitoring of SpO2 will allow for the measurement in the drop from baseline to the lowest point (nadir) during the test. Between the walk tests, the average drop will be calculated and compared.
Time frame: During the walk test
The time from the start of the test and the lowest (nadir) SpO2 will be recorded and compared between the walk tests.
Time frame: During the walk test
The absolute lowest (nadir) in SpO2 (%) recorded during the test will be recorded and compared.
Time frame: During the walk test
Measurement of the time taken to reach nadir in SpO2 will be recorded to help justify the length of the walk test
Hampshire Hospitals NHS Foundation Trust
Other
Comparison of the Standard 6-Minute Maximal Speed Walk Test Against a 6-Minute Normal Speed Walk Test as an Alternative and More Accurate Assessment for Ambulatory Oxygen Requirement.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06503913
COVID-19, Chronic Disease
Manchester, Greater Manchester, United Kingdom
View Trial DetailsNCT04322136
Cancer, Malignant Pleural Effusion
Nedlands, Western Australia, Australia
View Trial DetailsNCT05732571
COVID-19, Coronaviridae Infections
Nottingham, Notts, United Kingdom
View Trial DetailsNCT04619680
COVID-19, Cicatrix
Atlanta, Georgia, United States
View Trial Details